Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat in uncontrolled hypertension
NCT06336356Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of baxdrostat in hypertension (HTN), sponsored by AstraZeneca. Started Jun 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06336356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336356.